Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03840993 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of MT-2990 in Women With Endometriosis
A Phase 2 study, sponsored by Tanabe Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT03840993 is a Phase 2 study that has completed, run by Tanabe Pharma America. The registered enrollment target is 76 participants.
The verdict
NCT03840993, a Phase 2 study, has completed, sponsored by Tanabe Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of MT-2990 for treatment of moderate to severe endometriosis-related pain in women with surgically diagnosed endometriosis.
Interventions
- DRUG Placebo
- DRUG MT-2990
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2021-10-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03840993
The ClinicalTrials.gov registry entry for NCT03840993 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tanabe Pharma America, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03840993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03840993 about?
NCT03840993 is a clinical study titled "Safety and Efficacy Study of MT-2990 in Women With Endometriosis". The purpose of this study is to assess the safety and efficacy of MT-2990 for treatment of moderate to severe endometriosis-related pain in women with surgically diagnosed endometriosis.
What is the current status of trial NCT03840993?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2019-01-15. Estimated completion is 2021-10-05.
What interventions are being tested in trial NCT03840993?
The interventions under investigation include: Placebo (DRUG), MT-2990 (DRUG).
Who is sponsoring clinical trial NCT03840993?
This trial is sponsored by Tanabe Pharma America, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.